News

The settlement provides for a cross license of the Hathaway patents, licensed to Abbott by Indiana University, and the Sutura Nobles patents. In addition, Abbott has agreed to

The Phase I study will be a dose escalation trial involving up to 50 patients with hematological malignancies. The trial will evaluate safety, pharmacokinetic and pharmacodynamic properties of

Under the terms of the agreement, Maxygen will transfer to Sanofi Pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second generation vaccine.

A study to confirm the efficacy of oral interferon in the treatment of chronic cough will be launched in January at a major Texas university. This Phase II,

EpiCept will receive approximately $4.7 million in net proceeds from the offering. Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group acted as placement agent. EpiCept

The IND for the treatment of CLL is for an open-label, multi-dose, dose-escalation Phase I clinical trial for cancer that is expected to enroll up to 52 patients

Vivecon is a novel, small-molecule drug candidate that Myriad has designed to be taken orally and to inhibit viral maturation. Vivecon has been tested extensively for anti-viral activity

The objective of the trial is to define the maximum tolerated dose of Cloretazine (VNP40101M) when given to patients of 18 to 65 years of age with poor-prognosis

Erase-MI is a randomized, double-blind, placebo-controlled study assessing the use of PRT060128 upon diagnosis of STEMI, which is a type of heart attack that occurs when a coronary